Administration of GH-releasing peptide-2 (GHRP-2) represents a potential mode of therapy for children of short stature with inadequate secretion of GH. Requisite information to determine the dosing route and frequency for GHRP-2 consists of the pharmacokinetics (PK) and pharmacodynamics (PD) for this compound, neither of which have been previously evaluated in children. The purpose of this study was to characterize the PK and PD of GHRP-2 in children with short stature. Ten prepubertal children (nine boys and one girl; 7.7 Ϯ 2.4 yr old) received a single 1 g/kg iv dose of GHRP-2 over 1 min, followed by repeated (n ϭ 9) blood sampling over 2 h. GHRP-2 and GH were quantitated by specific RIA methods. PK parameters were calculated from curve fitting of GHRP-2 and GH vs. time data. Posttreatment plasma GH concentrations (normalized for pretreatment values) were used as the effect measurement. PD parameters were generated using the sigmoid E max model. Disposition of GHRP-2 best fit a biexponential function. GHRP-2 PK parameters (mean Ϯ SD) were: ␣ ϭ 13.4 Ϯ 9.7 h Ϫ1 , ␤ ϭ 1.3 Ϯ 0.3 h Ϫ1 , t 1/2␤ ϭ 0.55 Ϯ 0.14 h, AUC 03ϱ ϭ 2.02 Ϯ 1.37 ng/mL⅐h, C max ϭ 7.4 Ϯ 3.8 ng/mL, plasma clearance ϭ 0.66 Ϯ 0.32 L/h⅐kg, and apparent volume of distribution ϭ 0.32 Ϯ 0.14 L/kg. PK parameters for GH were: appearance rate constant ϭ 5.9 Ϯ 3.1h Ϫ1 , elimination t 1/2 ϭ 0.37 Ϯ 0.15 h, lag time ϭ 0.05 Ϯ 0.01 h, C max ϭ 50.7 Ϯ 17.2 ng/mL, T max ϭ 0.42 Ϯ 0.16 h, and AUC 03ϱ ϭ 47.9 Ϯ 26.1 ng/mL⅐h. PD parameters for GHRP-2 were: K e0 ϭ 1.13 Ϯ 0.94 h Ϫ1 , ␥ ϭ 13.15 Ϯ 9.44, E 0 ϭ 6.63 Ϯ 4.86 ng/mL (GH), E max ϭ 67.5 Ϯ 23.5 ng/mL (GH), and EC 50 ϭ 1.09 Ϯ 0.59 ng/mL. We concluded that 1) GHRP-2 produced a predictable and significant (i.e. compared to pretreatment values) increase in plasma GH concentrations; 2) the PK-PD link model enabled quantitative assessment of GHRP-2 modulation of serum GH levels; and 3) definition of the EC 50 for GHRP-2 will enable PD and PK evaluations of extravascular dosing regimens for children.
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A major potential clinical use for GHRP-2 is stimulation of GH secretion when endogenous secretion is inadequate. In many children with short stature and poor growth rates, the problem appears to be insufficient GH secretion, not an inability to produce GH. Evidence for this includes demonstration of subnormal 12-and 24-h GH pulsatile secretion profiles and a robust GH response when GHRH or GHRP-2 is administered to these children (10 -14) . Thus, this patient population may potentially benefit from treatment with a GH secretagogue such as GHRP-2.
A feature of the GHRP-2 that makes it an attractive treatment modality resides with its potential for administration by noninvasive methods. Previous investigations have demonstrated release of endogenous GH after the administration of GHRP-2 via the oral, sc, and intranasal routes as well as iv (3, (15) (16) (17) . This is a possible advantage over GH or GHRH, both of which must be administered parenterally. However, before large scale studies of the safety and efficacy of GHRP-2 can be conducted in children with GH deficiency, the pharmacokinetics (PK) and pharmacodynamics (PD) of this agent in pediatric patients must first be characterized. Therefore, we examined the PK and PD of iv GHRP-2 in children of short stature who were undergoing evaluation for GH deficiency.
Subjects and Methods
This study was of open design, with no blinding of the subjects or investigators. Ten short prepubertal children comprised the study population. These children were all at least 2 sd below the mean height for age, with mean of Ϫ3.03 Ϯ 0.16 sd. None of the children had evidence of chronic disease, syndromic disorder, or skeletal dysplasia. The single female patient had a normal karyotype. All children had a slow growth rate, delayed bone age, and low serum insulin-like growth factor I levels (Table 1) . Responses to GH stimulation tests, using standard secretagogues (e.g. arginine, insulin, or l-dopa) were variable, with five patients whose maximal GH response was more than 10 g/L and five patients whose GH response was less than 10 g/L. Six of the children (including the five whose maximal GH response was Ͼ10 g/L) had 12-h, overnight GH secretion studies. The mean GH concentration was low in each patient; the group mean was 2.3 g/L. Magnetic resonance imaging of the head was performed in each child, and no intracranial lesions were observed. Subjects were recruited by informed parental consent and, where appropriate (i.e. age Ն7 yr), by patient assent. The protocol was approved by the human research advisory committee of the University of Arkansas for Medical Sciences.
On the day of testing, the subjects arrived at the Day Medicine Unit of Arkansas Children's Hospital between 0700 -0800 h after an 8-h fast. There was one exception, that being a child whose testing began at 1300 h after a 4-h fast. An indwelling iv catheter was placed in each subject for the purpose of repeated blood sampling. Two basal (i.e. pretreatment) blood samples were obtained at Ϫ5 and 0 min for quantitation of both GHRP and GH. A single injection of GHRP-2 (1 g/kg) was then administered iv over a 60-s period of infusion. Repeated blood samples (1.0 mL each) were obtained at 5, 10, 20, 30, 45, 60, 75, 90 , and 120 min after the end of the GHRP-2 infusion. Blood specimens were collected into nonanticoagulant-containing glass tubes, where they were permitted to clot at room temperature for 40 min. The specimens were then centrifuged at 2500 ϫ g and 4 C for 10 min. Serum was separated and immediately frozen at Ϫ70 C until analysis.
Quantitation of GH from each serum specimen was performed using a commercial polyclonal RIA (Corning-Nichols Institute, San Juan Capistrano, CA). All GH samples from a given subject were run in the same assay, thereby minimizing the effect of interassay variability on pharmacokinetic profiles. Intra-and interassay coefficients of variation of this RIA method for GH were 3% and 8%, respectively. GHRP-2 serum concentrations were determined by a RIA developed and validated by Wyeth-Ayerst Research (Princeton, NJ), which used a polyclonal antibody provided by Dr. C. Y. Bowers. The calibration curve had a range of 62.5-2000 pg/mL. The interassay coefficients of variation and relative errors ranged from 5.8 -8.4% and Ϫ4.4 to Ϫ7.4%, respectively. The GHRP-2 standards, quality control samples, and study samples were analyzed in triplicate, and the mean values were used in performing calculations.
Individual serum concentration vs. time data for both GH and GHRP-2 were evaluated in each subject by use of the Siphar/Base software package (SIPHAR, version 4.0, SIMED, Creteil-Cedex, France). Initial polyexponential parameter estimates were generated with a peeling algorithm (18) . Final parameter estimates were obtained from curve fitting of individual datasets using a nonlinear, weighted, least squares algorithm, with the weight set as the reciprocal of the calculated plasma concentration (19) . Compartment model selection was made after application of the Akaike information criterion (20) . Additionally, goodness of fit for the serum concentration vs. time data was evaluated by assessment of the variance-covariance matrixes and the coefficients of variation for each polyexponential parameter (e.g. coefficients and exponents) calculated from a given model. Finally, model-dependent pharmacokinetic parameters were calculated for both GH and GHRP-2 according to previously described methods (21) .
The pharmacodynamics of GHRP-2 were examined by normalization of the posttreatment serum GH values to the mean of two pretreatment measurements to obtain the discrete value of ⌬GH. For the pharmacodynamic analysis, the ⌬GH values were used as a surrogate biomarker for the pharmacodynamic effect exerted by GHRP-2 in each subject. Visual inspection of the serum concentration vs. time data for both GHRP-2 and GH ( Fig. 1) and also of the ⌬GH vs. time values (data not shown) revealed a discordance in the serum concentration profiles compatible with an apparent equilibration delay between the serum concentrations of GHRP-2 and its pharmacological effect, as reflected by serum GH concentrations. Thus, the data suggested that a pharmacokinetic-pharmacodynamic model could be constructed that links the concentration of drug in the central (i.e. serum) compartment with the concentration of drug in an effect compartment (22) . Accordingly, concentration vs. effect profiles were then generated from the ⌬GH values for each subject by use of the sigmoid maximal effect model described by Holford and Sheiner (22) . Pharmacodynamic parameter estimates [maximal effect (E max ) serum concentration associated with 50% response as measured by post-treatment increase in serum concentration (EC 50 ), and sigmoidicity constant (␥)] were then calculated using an extended least squares algorithm with variance assumed to be constant (i.e. a homoscedastic model). The pharmacodynamic analysis was conducted using programs contained within the Siphar/D software package (SIPHAR, version 4.0, SIMED). Serum GH and GHRP-2 concentration data as well as the pharmacokinetic and pharmacodynamic parameter estimates are represented as the mean, sd, and range for the respective values. Relationships between subject age and the pharmacokinetic parameters for the entire study cohort were examined using a nonlinear, least squares, regression algorithm. All statistical tests were performed using subroutines contained within the S-STAT program (SIPHAR, version 4.0, SIMED) or in Excel (version 5.0, Microsoft Corp.). The level of significance accepted for all statistical analyses was ␣ ϭ 0.05.
Results
Ten short children received a single iv dose of GHRP-2 and completed the entire study. All subjects tolerated the infusion of GHRP-2 and all study-related procedures without apparent adverse effects. As illustrated in Fig. 1 , the mean (Ϯsd) serum GHRP-2 concentration vs. time curve revealed a multiphasic relationship that was best fit using a biexponential function. The elimination and distribution rate constants (i.e. ␣ and ␤, respectively) from the curve fit of the mean data were 1.32 and 10.58 h Ϫ1 , respectively, which yielded the following generalized equation that best described the mean serum vs. time concentration profile for GHRP-2: Cp tx ϭ 1.51 ϫ e Ϫ1.32 ϫ tx ϩ 13.11 ϫ e Ϫ10.58 ϫ tx , where Cp tx represents the plasma concentration of GHRP-2 at any given time point (i.e. tx). The excursion of serum concentrations ranged from 7.4 Ϯ 3.8 to 0.15 Ϯ 0.14 ng/mL over a period of 0.083-2.0 h, respectively, after administration of the GHRP-2 dose. A curve fit of the mean serum GHRP-2 vs. time data for all subjects revealed a rapid distribution (␣) phase with a mean distribution half-life (t 1 ⁄2 ␣ ) of 0.06 h, followed by a longer terminal elimination half-life (t 1 ⁄2 ␤ ) with a mean value of 0.52 h.
The polyexponential parameter estimates for GHRP-2 that resulted from the curve fits of the serum concentration vs. time data for each subject were used to calculate relevant pharmacokinetic parameters, which are contained and summarized in Table 2 . In each instance, a biexponential relationship provided the best fit of the serum concentration data.
The mean (Ϯsd) serum GH concentration vs. time data (Fig. 1 ) also revealed a multiphasic relationship that was best fit using a biexponential function. The appearance and elimination rate constants (i.e. K app and K el , respectively) from the curve fit of the mean serum concentration vs. time data were 4.97 and 1.75 h Ϫ1 , respectively, which yielded the following generalized equation that best described the mean serum concentration vs. time concentration profile for GH: Cp tx ϭ 131.62 ϫ e Ϫ1.75 ϫ tx ϩ 158.83 ϫ e
Ϫ4.97 ϫ tx
, where Cp tx represents the plasma concentration of GH at any given time point (i.e. tx). The apparent peak serum GH concentration from these data was 44.8 Ϯ 19.0 ng/mL. Serum GH concentrations declined in an apparent monoexponential fashion after the attainment of the peak concentration (i.e. T max ) at approximately 0.5 h and declined to 4.8 Ϯ 7.8 ng/mL 2 h after GHRP-2 administration. The curve fit of these data (Fig. 1 ) revealed a mean first order appearance rate constant (K app ) of 4.97 h Ϫ1 with a corresponding mean appearance t 1/2 of 0.14 h, and a mean apparent elimination rate constant (K e ) of 0.39 h Ϫ1 with a corresponding elimination t 1/2 of 0.4 h. Pharmacokinetic parameters for GH were calculated using the polyexponential parameters resulting from the curve fits of serum concentration vs. time data in each subject and are contained and summarized in Table 3 . As was true for the analysis of GHRP-2 data, a biexponential relationship provided the best fit of the serum GH concentration vs. time data for each subject (Fig. 1) . Three of the 10 subjects did not have quantifiable serum GH concentrations at the 2 h posttreatment collection point. This did not influence the determination of the pharmacokinetic parameters for these subjects, as each of them had a sufficient number of serum concentration vs. time points in the elimination phase to produce a reliable estimate of the apparent terminal elimination rate constant.
Examination of the pharmacokinetic parameters for both GHRP-2 and GH (Tables 2 and 3 , respectively) for apparent developmental dependence through attempts to correlate them with patient age revealed no statistically significant linear or nonlinear relationships. These same findings were apparent when the pharmacodynamic parameters for GHRP-2 (Table 4) were examined.
For each subject, the plot of the GHRP-2 serum concentration vs. effect (i.e. ⌬GH t ) data produced a counterclockwise hysteresis loop, which was consistent with an equilibration delay between the appearance of GHRP-2 in serum and its pharmacological effect (i.e. the stimulation of GH release and its appearance in serum). This particular pharmacodynamic relationship was present for all 10 subjects. Consequently, application of the sigmoid E max model enabled calculation of the pharmacodynamic parameters for GHRP-2 using GH as the surrogate marker of its pharmacological activity. These parameters are summarized in Table 4 .
Discussion
The pharmacokinetics of GHRP-2 found in our cohort of pediatric patients are similar to those previously reported in healthy adult volunteers after iv administration of the peptide (3). A comparison of the maximum GH response observed after GHRP-2 administration between these two studies revealed similarities in both the magnitude (i.e. mean values ϭ 44 g/L in children vs. 55 g/L in adults) and time of maximal response (i.e. average values ϭ 45-60 min for both). The GH responses observed after iv or sc GHRP-2 are also similar to those previously reported after the parenteral administration of GHRP-6, GHRP-1, or GHRH (3, 4, 23, 24) .
To our knowledge, our data represent not only the first report of GHRP-2 pharmacokinetics in pediatric patients, but TABLE 2. Individual pharmacokinetic parameters for GHRP-2 in short children also the first pharmacodynamic assessment of this peptide.
Comparison of the serum concentration vs. time profiles for both GHRP-2 and GH in our subjects reveals an equilibration delay in the attainment of peak GH response, a period that we believe corresponds to the time course of GHRP-2 action. This assertion is supported in part by the consistent observation of an equilibration delay between the serum concentrations of GHRP-2 vs. effect (i.e. ⌬GH t ) curves, reflected by the production of a counterclockwise hysteresis and our success in using the sigmoid E max model to effectively determine the pharmacodynamic parameters for GHRP-2. As previously reported by Holdford and Sheiner (22) , the successful application of this pharmacodynamic model suggests both linearity and predictability in the drug concentration vs. effect relationship. Given the fact that GH is a proximate biological marker of GHRP (and presumably, GHRP-2) activity (23, 24) , our assumptions entailed in the pharmacodynamic analysis of our data appear valid and reflective of the expected pharmacological response of GHRP-2.
Despite the apparent differences in serum GH pharmacokinetics reported after exogenous administration of the hormone (25) as opposed to the administration of GH secretagogues (26 -30) , both the pharmacokinetic and pharmacodynamic data from our study can be used to address the potential therapeutic efficacy of GHRP-2 in pediatric patients with GH insufficiency. First, the mean AUC for GH after the iv administration of a single 1 g/kg dose of GHRP-2 (i.e. 50.7 ng/mL⅐h) was approximately 50% of the AUC at steady state (i.e. 114.2 Ϯ 32.7 ng/mL⅐h) previously reported in a study of pediatric patients who received daily sc doses of 43 g/kg methionyl GH (25) . If one assumes linearity in the dose-response relationship for iv GHRP-2, administration of a single 2 g/kg iv dose would be expected to produce an AUC for GH that would be virtually identical to that observed under steady state conditions after sc administration of the currently recommended daily doses of recombinant human GH (25) , doses that have been shown to produce acceptable rates of linear growth in children who are GH deficient (30) . Second, both the C max (mean, 50.7 ng/mL) and E max values for GHRP-2 in our patient cohort (mean GH, 67.5 ng/mL) actually exceeded the average C max values for GH (37.6 Ϯ 11.6 ng/mL; range, 17.6 -49.5 ng/mL) after a single sc dose of 0.1 mg/kg methionyl GH to GH-deficient children (25) . Finally, the EC 50 for GHRP-2 in our study cohort (1.1 Ϯ 0.6 ng/mL) was substantially less than the C max value (7.4 Ϯ 3.8 ng/mL). This particular finding not only supports the adequacy of the 1 g/kg iv dose of GHRP-2 in producing a desirable biological effect, but also suggests that extravascular administration of this peptide by a route that could be associated with up to a 50% reduction in bioavailability may still produce an acceptable increase in the serum GH concentration sufficient to initiate and sustain a desired growth response. This hypothesis is being tested by our group in Keo, First order effect equilibrium rate constant; E 0 , serum GH concentration associated with no effect from GHRP-2; Y, slope factor of sigmoidicity for concentration vs. effect relationship; EC 50 , serum GHRP-2 concentration associated with 50% response as measured by posttreatment increase in serum GH concentrations; Emax, maximum attainable serum GH concentration after GHRP-2 administration derived from the pharmacokinetic-pharmacodynamic link model.
dose-ranging studies of oral and intranasal GHRP-2 that are currently underway.
In conclusion, both the pharmacokinetics and pharmacodynamics of iv administered GHRP-2 in short children are predictable and reflective of the potential for therapeutic application of this peptide. The data produced in this investigation will enable the selection of GHRP-2 doses for future evaluation of their bioavailability, safety, tolerance, and efficacy in children.
